Skip to the content

pharmaceutical daily

Pharmaceuticals, Biotechnology and Life Sciences

  • HOME
  • Pharma Business
  • About us
    • Media Kit
    • Privacy Policy
  • Contact
January 24, 2026 Off

Corvus Pharmaceuticals Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of the Underwriters’ Option to Purchase Additional Shares, Generating Gross Proceeds of Approximately $201M

By GlobeNewswire

SOUTH SAN FRANCISCO, Calif., Jan. 23, 2026 (GLOBE NEWSWIRE) — Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today…

January 24, 2026 Off

Roivant to Report Financial Results for the Third Quarter Ended December 31, 2025, and Provide Business Update on Friday, February 6, 2026

By GlobeNewswire

BASEL, Switzerland and LONDON and NEW YORK, Jan. 23, 2026 (GLOBE NEWSWIRE) — Roivant (Nasdaq: ROIV) today announced that it…

January 24, 2026 Off

XTL Announces Receipt of Nasdaq Notification Regarding Minimum Stockholders’ Equity Deficiency

By GlobeNewswire

RAMAT GAN, ISRAEL, Jan. 23, 2026 (GLOBE NEWSWIRE) — XTL Biopharmaceuticals Ltd. (Nasdaq:XTLB) (TASE:XTLB.TA) (the “Company” or “XTL”), announced today…

January 23, 2026 Off

Vaxcyte Advances Adult and Infant Programs for VAX-31, a Potential Best-in-Class, Next-Generation Pneumococcal Conjugate Vaccine

By GlobeNewswire

VAX-31 Adult Indication: Vaxcyte Doses First Participants in Phase 3 Study Evaluating Concomitant Administration of VAX-31 and Seasonal Influenza Vaccine…

January 23, 2026 Off

Adaptive Biotechnologies to Report Fourth Quarter and Full Year 2025 Financial Results on February 5, 2026

By GlobeNewswire

SEATTLE, Jan. 22, 2026 (GLOBE NEWSWIRE) — Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to…

January 22, 2026 Off

Erasca Announces Pricing of Upsized Public Offering of Common Stock

By GlobeNewswire

SAN DIEGO, Jan. 21, 2026 (GLOBE NEWSWIRE) — Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on…

January 22, 2026 Off

Plus Therapeutics to Provide Business Update and Host Conference Call on Thursday, January 22, 2026 at 9:00 A.M. ET

By GlobeNewswire

HOUSTON, Jan. 21, 2026 (GLOBE NEWSWIRE) — Plus Therapeutics, Inc. (NASDAQ: PSTV) (the “Company”), a healthcare company developing and commercializing…

January 22, 2026 Off

AEON Biopharma Reports BPD Type 2a Meeting with FDA and Shareholder Approval of the November Transactions

By GlobeNewswire

– AEON confirmed that earlier today it held its BPD Type 2a Meeting with the FDA, in line with prior guidance,…

January 22, 2026 Off

Madrigal Pharmaceuticals Announces Grant of Inducement Award under Nasdaq Listing Rule 5635(c)(4)

By GlobeNewswire

CONSHOHOCKEN, Pa., Jan. 21, 2026 (GLOBE NEWSWIRE) — Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics…

January 21, 2026 Off

Tempest Announces Record Date for Anticipated Dividend Distribution of Warrants to Stockholders

By GlobeNewswire

BRISBANE, Calif., Jan. 20, 2026 (GLOBE NEWSWIRE) — Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tempest”), a clinical-stage biotechnology company with a…

Posts pagination

Previous 1 … 11 12 13 … 3,605 Next

JOIN OUR COMMUNITY

Proudly powered by WordPress | Theme: Envo Magazine